These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 5097219)

  • 21. [Effect of 1-(4-oxyphenyl)-1-oxy-2-n-butylaminoethane sulfate on peripheral vascular diseases].
    Giulini SM; Agus GB; De Cristoforo A
    Minerva Cardioangiol; 1973 Jun; 21(6):434-8. PubMed ID: 4146376
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of clofibrate on blood viscosity in intermittent claudication.
    Dormandy JA; Gutteridge JM; Hoare E; Dormandy TL
    Br Med J; 1974 Nov; 4(5939):259-62. PubMed ID: 4425853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clofibrate and niacin in coronary heart disease.
    JAMA; 1975 Jan; 231(4):360-81. PubMed ID: 1088963
    [No Abstract]   [Full Text] [Related]  

  • 24. [The study of clofibrate. The viewpoint of Professor D. Kritchevsky interviewed by V. Fabbrocini].
    Kritchevsky D
    Minerva Med; 1979 Dec; 70(55):3808-9. PubMed ID: 523009
    [No Abstract]   [Full Text] [Related]  

  • 25. The influence of Clofibrat on plasma lipid levels.
    Szostak WB; Cybulska B; Ruzyllo E
    Mater Med Pol; 1971; 3(4):12-4. PubMed ID: 5162168
    [No Abstract]   [Full Text] [Related]  

  • 26. [Blood viscosity and hematocrit indices in arteriosclerosis].
    Kazakov IuM
    Vrach Delo; 1981 Feb; (2):27-8. PubMed ID: 7222603
    [No Abstract]   [Full Text] [Related]  

  • 27. [The clofibrate-dipyridamole combination in the prevention and therapy of arteriosclerotic vascular disease and its complications].
    Cucinotta D; Ferretti PG; Daccò L; Mazzera F
    G Clin Med; 1977; 58(11-12):475-86. PubMed ID: 608558
    [No Abstract]   [Full Text] [Related]  

  • 28. Serum lipids in an ambulary diabetic clientele. Effect of therapy with Atromidin (clofibrate).
    Bergqvist N
    Acta Med Scand; 1970 Mar; 187(3):213-8. PubMed ID: 5444978
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effect of Inderal on intermittent claudication in patients with obliterative arterial disease].
    Skawiński S; Wójcikiewicz O; Peiker W
    Pol Tyg Lek; 1971 Dec; 26(52):2019-21. PubMed ID: 5139589
    [No Abstract]   [Full Text] [Related]  

  • 30. The effectiveness of glycosaminoglycans in peripheral vascular disease therapy: a clinical and experimental trial.
    Corsi C; Bocci L; Cipriani C; Gazzini A; Marrapodi E
    J Int Med Res; 1985; 13(1):40-7. PubMed ID: 3884410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical evaluation of the therapeutic activity of the beta-pyridyl-carbinolic ester of clofibric acid].
    Silingardi V; Renzi R; Mora A; Di Prisco AU
    Minerva Med; 1973 Mar; 64(16):751-69. PubMed ID: 4579325
    [No Abstract]   [Full Text] [Related]  

  • 32. The effect of clofibrate on cholesterol induced aortic lesions.
    Fehér J; Bihari-Varga M; Varsáńyi M; Gerö S
    Br J Exp Pathol; 1972 Oct; 53(5):509-17. PubMed ID: 4263718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Study of clofibrate. The opinion of Prof. D. Kritchevsky].
    Fabbrocini V
    Minerva Cardioangiol; 1980 Nov; 28(11):759-60. PubMed ID: 7231692
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clofibrate therapy--the status quo].
    Reuter W
    Z Gesamte Inn Med; 1982 Jan; 37(2):59-63. PubMed ID: 7080553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained release papaverine in peripheral ischemia: report of 21 ambulatory cases with oscillometric studies.
    Tibbs EE
    South Med J; 1969 Jul; 62(7):875-8. PubMed ID: 5790687
    [No Abstract]   [Full Text] [Related]  

  • 36. [Treatment of some vascular diseases with the use of oxyphenyl-oxybutylamino-ethanol].
    Berezovsky M; Berstein S
    Prensa Med Argent; 1966 Sep; 53(36):1964-71. PubMed ID: 4384691
    [No Abstract]   [Full Text] [Related]  

  • 37. [Importance of the determination of HDL-cholesterol in the evaluation of arteriopathies of the lower extremities].
    Arber F; Darioli R; Monti M; Essinger A
    Schweiz Med Wochenschr; 1981 Dec; 111(50):1969-71. PubMed ID: 7330649
    [No Abstract]   [Full Text] [Related]  

  • 38. [Experiences with new Cosaldon forms].
    Dammann C
    Med Klin; 1969 Feb; 64(8):344-8. PubMed ID: 5783023
    [No Abstract]   [Full Text] [Related]  

  • 39. [Use of clofibrate and pyridinol carbamate singly or in combination in the antiarteriosclerotic therapy].
    Meciani L; Boeri S; Ricci G
    Minerva Cardioangiol; 1974; 22(7-8):512-42. PubMed ID: 4606052
    [No Abstract]   [Full Text] [Related]  

  • 40. Vascular symptomatic relief during administration of ethylchlorophenoxyisobutyrate (clofibrate).
    Albert M; Stansell MJ
    Metabolism; 1969 Aug; 18(8):635-45. PubMed ID: 4895062
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.